Literature DB >> 23665395

Glutathione metabolism and Parkinson's disease.

Michelle Smeyne1, Richard Jay Smeyne2.   

Abstract

It has been established that oxidative stress, defined as the condition in which the sum of free radicals in a cell exceeds the antioxidant capacity of the cell, contributes to the pathogenesis of Parkinson disease. Glutathione is a ubiquitous thiol tripeptide that acts alone or in concert with enzymes within cells to reduce superoxide radicals, hydroxyl radicals, and peroxynitrites. In this review, we examine the synthesis, metabolism, and functional interactions of glutathione and discuss how these relate to the protection of dopaminergic neurons from oxidative damage and its therapeutic potential in Parkinson disease.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-methyl-4-phenylpyridinium; 2-oxothiadolazine-4-carboxylate; 3,4-dihydroxyphenylacetic acid; 3-morpholinosydnonimine; 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine 3-carboxylic acid; ABC; ASK1; ATP-binding cassette transporter; BBB; BSO; COMT; DA; DAT; DHBT-1; DOPAC; GCL; GPX; GSH; GSSG; GST; Glutathione; Glutathione S-transferase; HVA; JNK; LDH; LPS; MDRP; MPP(+); MPTP; N-acetylcysteine; NAC; OTC; Oxidative Stress; P-glycoprotein; PD; Parkinson disease; Parkinson's disease; Pgp; ROS; SIN1; SNpc; Substantia nigra; TH; VMAT2; apoptosis signal-regulating kinase 1; blood–brain barrier; c-Jun N-terminal kinase; catechol-O-methyltransferase; dopamine; dopamine transporter; glutamylcysteine ligase; glutathione; glutathione S-transferase; glutathione disulfide; glutathione peroxidase; homovanillic acid; l-buthionine-(S,R)-sulfoximine; lactate dehydrogenase; lipopolysaccharide; multidrug resistance protein; reactive oxygen species; substantia nigra pars compacta; tyrosine hydroxylase; vesicular monoamine transporter 2; γ-glutamyl-N-transpeptidase; γGT

Mesh:

Substances:

Year:  2013        PMID: 23665395      PMCID: PMC3736736          DOI: 10.1016/j.freeradbiomed.2013.05.001

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  269 in total

1.  Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics.

Authors:  N Strazielle; J F Ghersi-Egea
Journal:  J Neurosci       Date:  1999-08-01       Impact factor: 6.167

Review 2.  Codrug: an efficient approach for drug optimization.

Authors:  N Das; M Dhanawat; B Dash; R C Nagarwal; S K Shrivastava
Journal:  Eur J Pharm Sci       Date:  2010-10-01       Impact factor: 4.384

3.  Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component.

Authors:  Carolina Perez-Pastene; Rebecca Graumann; Fernando Díaz-Grez; Marcelo Miranda; Pablo Venegas; Osvaldo Trujillo Godoy; Luis Layson; Roque Villagra; Jose Manuel Matamala; Luisa Herrera; Juan Segura-Aguilar
Journal:  Neurosci Lett       Date:  2007-03-14       Impact factor: 3.046

4.  Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells.

Authors:  Hao Hong; Ying Lu; Zhao-Ning Ji; Guo-Qing Liu
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

5.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.

Authors:  U Wüllner; P A Löschmann; J B Schulz; A Schmid; R Dringen; F Eblen; L Turski; T Klockgether
Journal:  Neuroreport       Date:  1996-03-22       Impact factor: 1.837

6.  Biomarkers for Parkinson's disease.

Authors:  Todd B Sherer
Journal:  Sci Transl Med       Date:  2011-04-20       Impact factor: 17.956

7.  New L-dopa codrugs as potential antiparkinson agents.

Authors:  Piera Sozio; Antonio Iannitelli; Laura Serafina Cerasa; Ivana Cacciatore; Catia Cornacchia; Gianfabio Giorgioni; Massimo Ricciutelli; Cinzia Nasuti; Franco Cantalamessa; Antonio Di Stefano
Journal:  Arch Pharm (Weinheim)       Date:  2008-07       Impact factor: 3.751

8.  Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease.

Authors:  J P Spencer; A Jenner; O I Aruoma; P J Evans; H Kaur; D T Dexter; P Jenner; A J Lees; D C Marsden; B Halliwell
Journal:  FEBS Lett       Date:  1994-10-24       Impact factor: 4.124

9.  Association of a polymorphism in the ABCB1 gene with Parkinson's disease.

Authors:  Marie Westerlund; Andrea Carmine Belin; Anna Anvret; Anna Håkansson; Hans Nissbrandt; Charlotta Lind; Olof Sydow; Lars Olson; Dagmar Galter
Journal:  Parkinsonism Relat Disord       Date:  2009-02-03       Impact factor: 4.891

10.  Ubiquitin-proteasome system impairment and MPTP-induced oxidative stress in the brain of C57BL/6 wild-type and GSTP knockout mice.

Authors:  Andreia Neves Carvalho; Carla Marques; Elsa Rodrigues; Colin J Henderson; C Roland Wolf; Paulo Pereira; Maria João Gama
Journal:  Mol Neurobiol       Date:  2012-11-06       Impact factor: 5.590

View more
  126 in total

1.  Phenolic Acid-based Poly(anhydride-esters) as Antioxidant Biomaterials.

Authors:  Almudena Prudencio; Jonathan J Faig; MinJung Song; Kathryn E Uhrich
Journal:  Macromol Biosci       Date:  2015-10-01       Impact factor: 4.979

2.  Echinacoside Protects Against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation.

Authors:  Qing Zhao; Xiaoyan Yang; Dingfang Cai; Ling Ye; Yuqing Hou; Lijun Zhang; Jiwei Cheng; Yuan Shen; Kaizhe Wang; Yu Bai
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

3.  Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.

Authors:  Thomas W Sedlak; Leslie G Nucifora; Minori Koga; Lindsay S Shaffer; Cecilia Higgs; Teppei Tanaka; Anna M Wang; Jennifer M Coughlin; Peter B Barker; Jed W Fahey; Akira Sawa
Journal:  Mol Neuropsychiatry       Date:  2018-04-17

Review 4.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies.

Authors:  Arvind Panday; Malaya K Sahoo; Diana Osorio; Sanjay Batra
Journal:  Cell Mol Immunol       Date:  2014-09-29       Impact factor: 11.530

5.  Therapeutic Role of a Cysteine Precursor, OTC, in Ischemic Stroke Is Mediated by Improved Proteostasis in Mice.

Authors:  Yanying Liu; Jia-Wei Min; Shelley Feng; Kalpana Subedi; Fangfang Qiao; Emily Mammenga; Eduardo Callegari; Hongmin Wang
Journal:  Transl Stroke Res       Date:  2019-05-02       Impact factor: 6.829

6.  A novel marker in acute central serous chorioretinopathy: thiol/disulfide homeostasis.

Authors:  Hasan Altinkaynak; Piraye Zeynep Kurkcuoglu; Mehtap Caglayan; Mücella Arıkan Yorgun; Nilay Yuksel; Pınar Kosekahya; Cemile Koca; Yasin Toklu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

7.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Authors:  Tanuja Bordia; Matthew McGregor; Roger L Papke; Michael W Decker; J Michael McIntosh; Maryka Quik
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

8.  Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.

Authors:  Xiaofeng Xu; Ning Song; Ranran Wang; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2015-09-18       Impact factor: 5.590

9.  Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NFκB pathway signaling targets in LPS/IFNγ -activated BV-2 microglia cells.

Authors:  Makini K Cobourne-Duval; Equar Taka; Patricia Mendonca; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-05-04       Impact factor: 3.478

10.  Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid.

Authors:  Reno C Reyes; Giordano Fabricio Cittolin-Santos; Ji-Eun Kim; Seok Joon Won; Angela M Brennan-Minnella; Maya Katz; Graham A Glass; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.